Quarterly ResultAug 6, 2026, 07:13 AM
Scholar Rock Q2 Net Loss $109.9M; Apitegromab FDA Review Advances
AI Summary
Scholar Rock Holding Corporation reported a net loss of $109.9 million for the second quarter of 2026, with a net loss per common share of $0.84. The company maintained a strong financial position with $492.1 million in cash, cash equivalents, and marketable securities, including $62.8 million from its ATM program. Key business highlights include the continued advancement of the apitegromab Biologics License Application (BLA) review by the FDA, with a PDUFA date of September 30, 2026, and the initiation of a Phase 2 study for apitegromab in FSHD.
Key Highlights
- Net loss for Q2 2026 was $109.9 million, a slight decrease from $110.0 million in Q2 2025.
- Net loss per common share was $0.84 for Q2 2026, down from $0.98 in Q2 2025.
- Cash, cash equivalents, and marketable securities totaled $492.1 million as of June 30, 2026.
- Received $62.8 million in net cash proceeds from the at-the-market (ATM) program during Q2 2026.
- Apitegromab BLA for SMA continues FDA review with two fill-finish facilities, PDUFA date September 30, 2026.
- Initiated Phase 2 FORGE study evaluating apitegromab in patients with facioscapulohumeral muscular dystrophy (FSHD).
- Phase 1 study for SRK-439 in healthy volunteers is ongoing, with topline data anticipated in late 2026.
Price Impact
More from SRRK